Amiodarone-induced thyrotoxicosis.

Abstract

Amiodarone-induced thyrotoxicosis (AIT) are not uncommon endocrinopathies. Clinicians are sometimes faced with difficult diagnostic and therapeutic situations. The disease pathophysiology is partially understood, explaining the lack of predictive factors for occurrence. Different international recommendations for their management have been published: the most recent in 2018 by the European Thyroid Association (ETA) (Ross et al., 2016; Bartalena et al., 2018). The purpose of this paper is to present the essential concepts for their management and to review the literature since 2018.

• Authors: Louis Schubert, Léopoldine Bricaire, Lionel Groussin
• Journal: Annales d'endocrinologie (Ann Endocrinol (Paris)) Vol. 82 Issue 3-4 Pg. 163-166 (Jun 2021) ISSN: 2213-3941 [Electronic] France
• PMID: 32409004 (Publication Type: Historical Article, Journal Article, Review)
• Copyright: Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Chemical References

• Anti-Arrhythmia Agents
• Amiodarone

Topics

• Amiodarone (adverse effects)
• Anti-Arrhythmia Agents (adverse effects)
• History, 21st Century
• Hypothyroidism (chemically induced, therapy)
• Practice Guidelines as Topic
• Thyroid Function Tests
• Thyrotoxicosis (chemically induced, diagnosis, therapy)